Sir -The data on secondary leukaemia following etoposide chemotherapy are still far from clear. It seems to be associated particularly with high doses in children and has a short latency (2-3 years). Two recently published large studies incorporating etoposide in Hodgkin's disease over a 10 year period report no cases of leukaemia so far (Hancock et al., 1992; Cullen et al., 1994) . This includes our own Central Lymphoma Group study in which etoposide is combined with bleomycin (Cullen et al., 1994) . The MRC adjuvant chemotherapy study in high-risk stage I nonseminomatous germ cell tumours of the testis (NSGCTT) will be published shortly. In 122 patients receiving two courses of BEP, there have been no cases of leukaemia so far with a median follow-up of more than 2 years.
At the time of adopting any therapeutic strategy, one must carefully weigh up efficacy and toxicity. This is no more important in potentially curative adjuvant therapy than in potentially curative treatment of more advanced disease.
I suspect one of the reasons Dr Colls and his team switched from PVB to BEP (although this might have been forgotten when the above letter was written) was that BEP was more effective in the definitive trial in advanced disease as well as having less short-term subjective toxicity (Williams et al., 1987 
